Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study.

ABSTRACT:

Objective

Interferon-γ-inducible protein-10 (IP-10 or CXCL10) plays a role in inflammatory cell migration and epithelial cell survival and migration. It is expressed in higher levels in the colonic tissue and plasma of patients with ulcerative colitis (UC). This phase II study assessed the efficacy and safety of BMS-936557, a fully human, monoclonal antibody to IP-10, in the treatment of moderately-to-severely active UC.

Design

In this 8-week, phase II, double-blind, multicentre, randomised study, patients with active UC received placebo or BMS-936557 (10 mg/kg) intravenously every other week. The primary endpoint was the rate of clinical response at Day 57; clinical remission and mucosal healing rates were secondary endpoints. Post hoc analyses evaluated the drug exposure-r

SUBMITTER: Mayer L 

PROVIDER: S-EPMC3933070 | biostudies-literature | 2014 Mar

REPOSITORIES: biostudies-literature